Clinical trials: Clarithromycin, completed
Asthma
Chronic Bronchiolitis or Resistant Asthma?
Chronic Bronchiolitis or Resistant Asthma? Testing a way to diagnosis and treatment
- Trial name
- NCT00368342
- Testing
- Erythromycin, Azithromycin , Clarithromycin
- Sponsor
- Baqiyatallah Medical Sciences University
Healthy
Bioequivaelnce Study of Clarithromycin 250 mg/5 mL Powder for Oral Suspension Under Fed Conditions
To compare the single-dose oral bioavailability of clarithromycin 250 mg/5 mL powder for oral suspension of Ranbaxy Laboratories with Biaxin 250 mg/5 mL granules for oral suspension in healthy, adult, human, male subjects under…
- Trial name
- NCT00775372
- Testing
- Clarithromycin 250mg/5mL
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Helicobacter Infections
Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication
Clarithromycin-based triple therapy containing a proton-pump inhibitor (PPI) twice daily, amoxicillin 1g twice daily, and clarithromycin 500 mg twice daily for 7 days is one of the standard firs-line therapy for Helicobacter…
- Trial name
- NCT00816140
- Testing
- Cravit based triple therapy, Klaricid based triple therapy
- Where
- Taiwan
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
H Pylori Infection, H Pylori Gastritis
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
H. pylori is an infection of the stomach that can cause chronic gastritis, gastric cancer and peptic ulcer disease. The goal of this study is to screen people for this infection and offer treatment for those who test positive for…
- Conditions
- H Pylori Infection, H Pylori Gastritis, Gastric Cancer
- Trial name
- NCT07224035
- Testing
- PYTEST® 14C-Urea Breath Test, VOQUEZNA® Triple Pak®
- Where
- United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- University of Miami
Helicobacter Pylori Infection
Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy
Background：Helicobacter pylori infection is a well-established risk factor for peptic ulcer disease and gastric cancer. It's now a consensus of experts that H.pylori infection should be treated once it is recognized.
- Trial name
- NCT06156085
- Testing
- Vonoprazan and Amoxicillin, Lansoprazole, Amoxicillin, Clarithromycin and Metronidazole
- Where
- Taiwan
- Volunteers
- 337 people
- Sponsor
- Fu Jen Catholic University Hospital
Helicobacter Pylori Infection
Vonoprazan-based Therapy Versus Standard Regimen for Helicobacter Pylori Infection Management
Appropriately, half of the global population is infected with H. pylori, and it is now recognized that it causes at least 95% of all gastric cancers. Currently, the main challenge in the field of H.
- Trial name
- NCT05614934
- Testing
- standard Clarithromycin triple therapy, Vonoprazan triple therapy, Vonoprazan dual therapy
- Where
- Egypt
- Volunteers
- 132 people
- Sponsor
- Alexandria University
Healthy
A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants
The purpose of this study is to assess the effects of strong cytochrome P450 (CYP) 3A4 inhibitors (Itraconazole and Clarithromycin), on pharmacokinetics (PK) (study of the way a drug enters and leaves the blood and tissues over…
- Trial name
- NCT02197884
- Testing
- JNJ-54861911, 25 mg, Itraconazole 200 mg, Clarithromycin 500 mg
- Where
- Belgium
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Stomach Ulcer
Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy
The purpose of this study is to evaluate the ulcer healing efficacy of rebamipide in comparison with omeprazole in Helicobacter pylori-positive gastric ulcer after eradication therapy.
- Trial name
- NCT00272467
- Testing
- Rebamipide, Omeprazole
- Where
- 7 sites in China, South Korea
- Volunteers
- 132 people
- Sponsor
- Korea Otsuka International Asia Arab
B-cell Malignancies
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
The primary objective of this study was to assess the steady-state zanubrutinib pharmacokinetics (PK) when co-administered with moderate and strong cytochrome P450 family 3 subfamily A (CYP3A) inhibitors.
- Trial name
- NCT04551963
- Testing
- Zanubrutinib, Fluconazole, Diltiazem
- Where
- 7 sites in Australia
- Volunteers
- 26 people
- Sponsor
- BeiGene
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
RCT: Triple vs Sequential vs Concomitant Therapy H Pylori
Triple therapy (TT) comprising proton pump inhibitor (PPI), amoxicillin 1g and clarithromycin 500mg twice daily has long been considered one of the standard treatment for H.
- Trial name
- NCT02092506
- Testing
- 10 day triple therapy, 10 day sequential therapy, 10 day concomitant therapy
- Where
- Singapore
- Volunteers
- 462 people
- Sponsor
- Changi General Hospital
Lymphoma
Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
The purpose of this study is to see if a treatment with Biaxin (clarithromycin) which is an antibiotic given by mouth for 3 months can delay the growth of your lymphoma or shrink the lymphoma.
- Trial name
- NCT00461084
- Testing
- BIAXIN (CLARITHROMYCIN)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anovulation, Disorder Due Cytochrome P450 CYP2D6 Variant
Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene
Aim of the study is the clinical validation of the metabolism and the pharmakokinetic of Clomifen in correlation to CYP2D6 and inhibition of CYP3A4.
- Conditions
- Anovulation, Disorder Due Cytochrome P450 CYP2D6 Variant, Cytochrome P450 CYP3A Enzyme Deficiency
- Trial name
- NCT01289756
- Testing
- Clomiphene, clomiphene and paroxetine, clomiphene and clarithromycin
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Helicobacter Pylori Infection
Triple Therapy With Tegoprazan in H. Pylori Positive Patients
The current study is designed to demonstrate the non-inferiority of tegoprazan triple therapy (tegoprazan, amoxicillin, and clarithromycin; hereinafter TAC) to lansoprazole triple therapy (lansoprazole, amoxicillin, and…
- Trial name
- NCT03498456
- Testing
- Tegoprazan/Amoxicillin/Clarithromycin, Lansoprazole/Amoxicillin/Clarithromycin
- Where
- South Korea
- Volunteers
- 284 people
- Sponsor
- HK inno.N Corporation
Helicobacter Pylori
A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication
We aim to assess and compare the effectiveness of clarithromycin- and furazolidone-based regimens as primary therapies in eradicating H. pylori.
- Trial name
- NCT03716622
- Testing
- Furazolidone, Clarithromycin
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection
A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients
The current study is designed to demonstrate the non-inferiority of CJ-12420-based triple therapy (CJ-12420, amoxicillin and clarithromycin) versus lansoprazole-based triple therapy (lansoprazole, amoxicillin and clarithromycin)…
- Trial name
- NCT03317223
- Testing
- CJ-12420/Clarithromycin/Amoxicillin
- Where
- South Korea
- Volunteers
- 350 people
- Sponsor
- HK inno.N Corporation
Pulmonary Diseases
Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease
To date key drugs in the treatment of MAIS, M.malmoense and M.xenopi (Opportunist Mycobacteria have been rifampicin and ethambutol. Clarithromycin and Ciprofloxacin are active in vitro against these species of mycobacteria.
- Trial name
- NCT00367913
- Testing
- Addition of clarithromycin to rifampicin and ethambutol, Addition of Ciprofloxacin to rifampicin and ethambutol, Vaccination with M.vaccae
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- British Thoracic Society
Healthy Volunteers
Selection of Antibiotic Resistance by Azithromycin and Clarithromycin in the Oral Flora
Resistance to antibiotics is a major public-health problem and studies linking antibiotic use and resistance have shown an association not a causal effect.
- Trial name
- NCT00354952
- Testing
- Macrolides (azithromycin or clarithromycin)
- Where
- Belgium
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- Universiteit Antwerpen
Helicobacter Pylori Infection
Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori
This randomized controlled study aimed to evaluate whether adding bismuth to the standard first-line triple therapy could improve the eradication rate of Helicobacter pylori (H. pylori). A total of 162 patients with H.
- Trial name
- NCT03108287
- Testing
- RAK therapy, RBAK therapy
- Volunteers
- 162 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Mycobacterium Avium-intracellulare Infection, HIV Infections
A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS
This study is designed to evaluate the efficacy and safety of clarithromycin given orally at 1 of 3 doses to treat disseminated Mycobacterium avium complex infections (MAC) in patients with AIDS.
- Trial name
- NCT00000644
- Testing
- Clarithromycin
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other
Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"
The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.
- Trial name
- NCT03219723
- Testing
- Vonoprazan, Amoxicillin hydrate, Clarithromycin
- Where
- Japan
- Volunteers
- 560 people
- Sponsor
- Takeda